KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Exact Sciences (EXAS) over the last 16 years, with Dec 2024 value amounting to $600.9 million.

  • Exact Sciences' Cash & Equivalents rose 34.00% to $789.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $789.0 million, marking a year-over-year increase of 34.00%. This contributed to the annual value of $600.9 million for FY2024, which is 0.74% down from last year.
  • Exact Sciences' Cash & Equivalents amounted to $600.9 million in FY2024, which was down 0.74% from $605.4 million recorded in FY2023.
  • In the past 5 years, Exact Sciences' Cash & Equivalents ranged from a high of $1.5 billion in FY2020 and a low of $242.5 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $482.9 million, with a median of $600.9 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 741.33% in 2020, then plummeted by 78.85% in 2021.
  • Yearly analysis of 5 years shows Exact Sciences' Cash & Equivalents stood at $1.5 billion in 2020, then plummeted by 78.85% to $315.5 million in 2021, then fell by 23.13% to $242.5 million in 2022, then surged by 149.65% to $605.4 million in 2023, then fell by 0.74% to $600.9 million in 2024.